LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients
NCT01167309
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
Secondary Hyperparathyroidism
Interventions
DRUG:
LEO 27847
Sponsor
LEO Pharma